DIAGNOSIS OF LEISHMANIASIS

Abstract: There is disclosed a method for diagnosing leishmaniasis comprising: (a) obtaining a sample from a patient suspected of being infected with a Leishmania parasite, wherein the sample contains antibodies from the patient; and (b) determining the presence of antibodies that bind to a K39 repeat unit antigen from the sample. There is further disclosed an antigen common to many species of Leishmania that can be used as a diagnostic agent.

Description: DIAGNOSIS OF LEISHMANIASIS Technical Field of the Invention The present invention provides a method for diagnosing leishmaniasis in a patient suspected of being infected with the parasitic protozoa .Leishmania. The present invention further provides a diagnostic kit for use in diagnosing Leishmania, and an antigen useful for diagnosing the presence of Leishmania and as a vaccine to prevent infection with Leishmania. Background of the Invention The transmission of pathogenic Leishmania involves an injection of extracellular promastigotes into a mammalian host by an infected sandfly. The promastigotes rapidly attach and enter monocytes and cells of the reticuloendothelial system, where they transform into amastigotes and multiply within phagolysosomes. Analysis of the interaction of Leishmania promastigotes with the target host cell suggests that both parasite and host molecules are involved in cell adhesion. Clinical symptoms of leishmaniasis range from self-healing skin lesions to diffuse cutaneous and mucosal manifestations, or severe visceral involvement of the spleen, liver and lymph nodes (visceral leishmaniasis or VL). Visceral leishmaniasis is generally caused by Leishmania donovani in Africa and India, L. infantum in Southern Europe or L. chagasi in Latin America. In VL, high levels of parasite specific antibodies are observed prior to detection of antigen specific T cell responses (Ghose et al., Clin. Exp. Immunol. 40:318-326, 1980). This antibody response has been exploited for serodiagnosis of infection with L. chagasi and L. donovani. The current World Health Organization's estimate of 12 million cases of leishmaniasis and recent epidemics of visceral leishmaniasis in Sudan and India highlight the need for more effective early diagnosis and therapeutic agents. Also at least 400,000 new cases of VL are diagnosed annually. The current diagnostic tests to measure an antibody response use whole or lysed parasites. Therefore, there is a need in the art to improve the diagnostic accuracy for diagnosing VL early while the potentially fatal disease is more treatable. Recovery from leishmaniasis correlates with the development of specific T lymphocyte responses and usually confers long-lasting immunity against reinfection (Carvalho et al., ./. Clin. Invest. 76:2066-6, 1985 and Carvalho et al., J. Immunol. 135:4144-8, 1985). Both recovery from disease and resistance to reinfection are dependent on the development of specific T lymphocyte responses. Interferon gamma (IFN-γ) is a product of activated T cells, has demonstrated anti-leishmania activity in vitro (Murray et al., J. Clin. Invest. 72:1506, 1983 and Nacy et al., J. Immunol. 135:1305, 1985), and in vivo (Reed et al., J. Immunol. 132:3116, 1984 and Murray et al., J. Immunol. 1348:2290, 1987) and has been used effectively in the clinical treatment of leishmaniasis (Harms et al., Lancet 10:1287, 1989 and Badaro et al., N. Engl. J. Med. 322:16, 1990). One antigen, called gp63, has been cloned (Miller et al., Mol. Biochem. Parasitol. 38, 261 -21 A, 1990) and was found to be a metalloprotease and is highly conserved among different species of Leishmania (Etges et al., J. Biol. Chem. 261:9098, 1986; Chaudhuri et al., Mol. Biochem. Parasitol. 27:43, 1988: Chaudhuri et al., J. Biol. Chem. 264:7483, 1989; Colmer-Gould et al., J. Exp. Med. 162:902, 1985; and Button et al., J. Exp. Med. 167:724, 1988). Gp63 is relatively abundant on both the infective promastigote stage and the intracellular amastigote stage (Frommel et al., Mol. Biochem. Parasitol. 38:25-32, 1990 and Medina-Acosta et al., Mol. Biochem. Parasitol. 37:263, 1989). Gp63 is important for both parasite entry into macrophages (Russel and Wilheim, ./. Immunol. 136:2613, 1986; Chang et al., Proc. Natl. Acad. Sci. USA 83:100, 1986; Wilson and Hardin, J. Immunol. 141:265, 1988; and Mosser and Edelson J. Immunol. 135:2785, 1985) and subsequent survival within the phagosome (Chaudhuri et al., J. Biol. Chem. 264:7483, 1989). Immunization with native gp63 in vivo partially protected susceptible mice against cutaneous disease (Handman and Mitchell Proc. Natl. Acad. Sci. USA 82:5910, 1985 and Russel and Alexander J. Immunol. 140:1274, 1988). Moreover, recombinant gp63 expressed in Salmonella conferred partial protection by oral immunization against Leishmania major infection in resistant mice (Yang et al., J. Immunol. 145:2281, 1990). Both native gp63 and recombinant gp63 elicited strong proliferative responses, as well as IFN-γ production, from leishmaniasis patients with a spectrum of clinical disease (Russo et al., J. Immunol. 147:3575, 1991). Summary of the Invention The present invention provides a method for diagnosing leishmaniasis comprising: (a) obtaining a sample from a patient suspected of being infected with a Leishmania parasite, wherein the sample contains antibodies from the patient; and (b) determining the presence of antibodies that bind to a K39 repeat unit antigen from the sample. Preferably the inventive method is a serodiagnostic method utilizing sera from the individual suspected of harboring a Leishmania parasite. Preferably the antigen used is one or a plurality of K39 repeat sequences, wherein the K39 repeat sequence comprises the amino acid sequence (in single letter designation) L E Q Q L R (D/E) S E (E/A) R A A E L A S Q L E (A/S) T (A/T) A A K (M/S) S A E Q D R E (N/S) T R A (T/A) or (in three letter designation) Leu Glu Gin Gin Leu Arg (Asp/Glu) Ser Glu (Glu/Ala) Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu (Ala/Ser) Thr (Ala Thr) Ala Ala Lys (Met/Ser) Ser Ala Glu Gin Asp Arg Glu (Asn/Ser) Thr Arg Ala (Thr/Ala) (SEQ ID NO:3). Preferably, the inventive method further comprises the step of determining the presence of antibodies that bind to a native or recombinant gp63 polypeptide. The present invention further provides a diagnostic kit for evaluating a patient antibody-containing sample for the presence of anύ-Leishmania parasite antibodies, comprising a K39 repeat unit antigen. Preferably, the K39 repeat unit antigen is bound to a solid phase. Preferably, the diagnostic kit further comprises an anti-human antibody conjugated to a detection moiety. Preferably the antigen used is one or a plurality of K39 repeat sequences, wherein the K39 repeat sequence comprises the amino acid sequence Leu Glu Gin Gin Leu Arg (Asp/Glu) Ser Glu (Glu/Ala) Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu (Ala/Ser) Thr (Ala Thr) Ala Ala Lys (Met/Ser) Ser Ala Glu Gin Asp Arg Glu (Asn/Ser) Thr Arg Ala (Thr/Ala) (SEQ ID NO:3). Most preferably, the diagnostic kit further comprises a gp63 polypeptide, in combination with a K39 repeat unit antigen. Brief Description of the Drawings and Sequences Figure 1 shows the expression and purification of recombinant K39 (rK39) antigen. The gels shows Coomassie blue-stained 12% SDS-polyacrylamide gel of molecular weight markers (lane 1), E. coli lysates from uninduced cells (lane 2), and induced cultures (lane 3) of clone K39, and purified rK39 (lane 4, 2 μg). Figure 2 shows reactivity of patient sera with rK39. Blots containing L. chagasi promastigote lysate (lane 1, lOμg), purified rK39 (lane 2, 50 ng) and T. cruzi epimastigote lysate (lane 3, 10 μg) were probed with individual L. chagasi VL sera (A- C), individual L. donovani VL sera (D-F), or pooled mucosal leishmaniasis (G, n=4), cutaneous leishmaniasis (H, n-4), or T. cruzi infection (I, n=5) sera. Pooled normal human sera (n=3) and no primary antibody controls are shown (J and K, respectively). Bound antibody was detected with 125 I-protein A. Figure 3 shows a Southern blot analysis of the LcKin gene sequences. Genomic DNA (2.5 μg/lane) from L. chagasi digested with Bam HI (lane 1), Hind III (lane 2) and Pst I (lane 3) or Pst I digested DNA from L. amazonesis (lane 4), L. braziliensis (lane 5), L. guyanesis (lane 6), L. donovani (lane 7), L. infantum (lane 8), L. major (lane 9), or T. cruzi (lane 10) were analyzed by Southern blotting. The blots were probed (A) with a 2.4 kb Hind III fragment from the LcKin homology domain or (B) with the 915 bp repetitive insert of K39. Figure 4 shows reactivity of rabbit anti-rK39 antiseru on recombinant and native leishmania lysates. A is an immunoblot of purified rK39 (50 ng per lane) transferred from 12% SDS-polyacrylamide gels and probed with preimmune rabbit serum (lane 1) or rabbit anti-rK39 (lane 2). B is an immunoblot of L. chagasi promastigote (lanes 1 and 5, 10 μg) and amastigote (lanes 2 and 6 10 μg) lysates or L. amazonensis promastigote (lanes 3 and 7, 10 μg) and amastigote (lanes 4 and 8, 10 μg) lysates, transferred from 7.5% SDS-polyacrylamide gels and probed with preimmune rabbit serum (lanes 1-4) or rabbit anti-rK39 (lanes 5-8). C is an immunoblot showing reactivity of rabbit antisera raised against L. chagasi ribosomal protein PO, described in Skeiky et al. (J. Exp. Med. 176:201, 1992), with lanes 1-4 of B. Figure 5 shows an ELISA evaluation of patient seroreactivity on L. chagasi promastigote lysate (panel A) or purified rK39 (panel B). Absorbance values (mean + SEM) of Brazilian VL (VL-B, n=57), Sudanese VL (VL-S, n=52), T. cruzi infection (Tc, n=35), Brazilian cutaneous leishmaniasis (CL-B, n=13), Sudanese cutaneous leishmaniasis (CL-S, n=13) mucosal leishmaniasis (ML, n=15) and normal (n=15) sera. Figure 6 shows patient sera reactivities against recombinant gp63. All sera samples were diluted 1 : 100 and assayed by an ELISA technique. Individual absorbance values are represented by dots; horizontal and vertical bars represent the mean +/- 95% confidence limit (Student's t-test), respectively. The abbreviations are visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (MCL). SEQ ID NO: 1 is the amino acid sequence for K39. SEQ ID NO: 2 is the DNA sequence encoding a K39 polypeptide. SEQ ID NO:3 is the amino acid sequence of a 39 amino acid repeat unit antigen. Detailed Description of the Invention The present invention provides a method for diagnosing VL and a diagnostic kit for VL. The present invention was made possible by the discovery of a K39 gene and its DNA sequence and deduced amino acid sequence having a plurality of antigenic 39 amino acid repeat units. The K39 gene was found in an attempt to characterize leishmania antigens recognized by a spectrum of VL patients, including VL patients infected with either L. donovani or L. chagasi. A L. chagasi genomic DNA expression library was screened with sera obtained from a patient having VL caused by L. donovani. From approximately 32,000 recombinants screened, seven clones were selected based upon reactivity with this patient's sera. The seven clones contained inserts ranging from 0.9 kb to 2.6 kb and expressed immunoreactive recombinant proteins of 35 kDa to 100 kDa. Clone K39 was exceptionally reactive with the test serum. Recombinant K39 antigen (rK39) migrated on Coomassie-stained SDS-PAGE as a 39 kDa protein in induced bacterial extracts (Figure 1, lane 3). The protein was purified by ammonium sulfate fractionation and preparative isoelectric focusing (Figure 1, lane 4) with a yield of 25-30 mg per liter. The DNA and deduced amino acid sequences of the insert of clone K39 were determined and are provided in SEQ ID NOs: 1 and 2 herein. The DNA sequence contained a single open reading frame encoding 298 amino acids with a predicted molecular weight of 32.7 kDa and a pi of 4.4. Clone K39 contains an additional 6.2 kDa of plasmid fusion sequences. In this sequence was noted 6.5 copies of a randomly arrayed 39 amino acid repeat sequence. SEQ ID NO: 3 shows the consensus sequence of the repeat unit. To further characterize this gene, clones containing sequences flanking the K39 gene fragment were isolated from the L. chagasi library using a K39 insert probe. Sequence analysis of one overlapping clone, LcKin, showed that the open reading frame extended for 1971 base pairs in the 5' direction, encoding 657 nonrepeditive amino acids. 5' to the putative ATG initiation codon, 454 base pairs of sequence were obtained with multiple termination codons in each reading frame. Partial characterization of clones containing 3' flanking sequences indicated that the repeat domain extended for approximately 3 to 4 kb. GenPept and Swiss-Protein data bank searches revealed similarity between LcKin and several members of the superfamily of kinesin-related proteins, particularly in the N-terminal motor domain. A relatively high level of sequence conservation was observed in the putative ATP and microtubule binding domains (Yang et al., Cell 56:879, 1989). The remaining 500 residues showed little similarity to sequence of the tail regions of kinesin and myosin of a number of species. Secondary structure analysis predicted that this portion of LcKin (amino acids 426-955) contain greater than 90% helical structure, a feature characteristic of a coil-coiled tail regions of several motor proteins. Therefore, the repetitive epitope of the rK39 antigen appears to be present in L. Cxhagasi as part of the tail region of a leishmania kinesin-related protein. The present invention provides an identification of a 230 kDa antigen of L. Cxhagasi, LcKin, with sequence homology to the kinesin superfamily of motor proteins. The gene is predominantly expressed by tissue amastigotes. The DNA sequence is present in at least seven diverse species of Leishmania. The DNA sequence further comprises an extensive repetitive domain containing a 39 amino acid repeat unit. Southern analysis showed the repeat unit of LcKin to be variable among species, but was closely related in L. chagasi and L. donovani. Most significantly, there are high antibody titers in 98% of Brazilian VL patients to rK39, a recombinant antigen containing 6.46 copies of the 39 amino acid repeat sequence. Similar antibody levels were detected in 100% of tested Sudanese VL patients. These data indicate conservation of the repeat sequence between L. chagasi and L. donovani. The present cloning of LcKin represents the first characterization of a gene encoding a protozoan motor protein. These microtuble based motors are involved in such varied intracellular processes as organelle and synaptic vescicle transport, chromosome segregation and spindle pole separation, nuclear fusion, protein sorting a flagellar beating. This tail domain is usually characterized by a predominantly alpha- helical structure which likely forms a coil interacting with different intracellular ligands which determine its function. The LcKin gene product is similar to members of this family in primary sequence, particularly in the putative ATP and microtubule binding domains, as well as in predicted secondary structure. The inventive feature of LcKin was the high prevalence of antibody specific to the rK39 repeat sequence in VL patients from geographically distinct endemic regions of Brazil and the Sudan. Therefore, the rK39 repeat antigen is useful as a vaccine and as an antibody-binding antigen for a diagnostic kit for the detection and diagnosis of VL. Moreover, the inventive method for diagnosing VL using rK39 was specific for VL patients. False positives were not seen in normal patients, even normal patients from the endemic areas of Brazil and the Sudan. These data also reflect relatedness among members of the L. donovani complex. The data described herein provide a thorough analysis of patient antibody responses to a purified recombinant antigen (rK39) of L. chagasi and show a marked restriction of this response to L. chagasi and L. donovani infected patients with VL with 98% and 100% positivity in this group.. The inventive diagnostic kit and the inventive method for diagnosing VL and distinguishing VL from other infectious diseases with similar clinical presentations provides a needed tool in a clinicians hands in endemic areas of the world. Therefore, antibody reactivity to rK39 is an improved replacement for promastigote-based serological tests for the diagnosis of acute VL. The rK39 antigen is an immunodominant B cell epitope comprising one or more copies of the Leu Glu Gin Gin Leu Arg (Asp/Glu) Ser Glu (Glu/Ala) Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu (Ala/Ser) Thr (Ala/Thr) Ala Ala Lys (Met Ser) Ser Ala Glu Gin Asp Arg Glu (Asn Ser) Thr Arg Ala (Thr/Ala) (SEQ ID NO:3) 39 amino acid repeat sequence. Preferably the K39 antigen comprises from 1 to about 7 copies of the 39 amino acid sequence. Most preferably, the K39 antigen comprises about 6 copies of this sequence. Gp63 is a major surface glycoprotein of Leishmania parasites, is highly conserved among species and is expressed in both infective and intracellular stages. The gp63 gene of L. chagasi has been cloned, analyzed and described in Miller et al. (Mol. Biochem. Parasitol. 39:276, 1990). It is significant to note that the sequence of L. chagasi was found to differ significantly from that published for L. major (Button et al. J. Exp. Med. 167:724, 1988). The predicted protein sequences of gp63 from L. major andL. chagasi are closely related. Gp63 is a surface metalloprotease (Bouvier et al., Mol Biochem. Parasitol. 37:235, 1989 and Medina-Acosta et al., Mol Biochem. Parasitol. 37:263, 1989) that is also important for parasite entry into macrophages and survival within the phagosome. Native gp63 (ngp63) and recombinant gp63 (rgp63) elicited strong proliferative responses and IFN-γ production from leishmaniasis patients with a spectrum of clinical disease. The present invention further found the prevalence of gp63-specific antibodies among patients with clinically and geographically diverse leishmaniasis to provide a further useful diagnostic tool alone or in combination with the use of the K39 antigen for diagnosis of VL. The prevalence of gp63-specific antibody among leishmaniasis and other disease groups was examined by an ELISA technique (described in Example 4 herein). All leishmaniasis sera were obtained from patients with active disease, and included Brazilian visceral, cutaneous or mucosal leishmaniasis from a study area in Bahia, Brazil or from biopsy-positive patients in the Sudan. Leprosy sera were from patients in Haiti where leishmaniasis has not been reported. Normal control sera were from normal volunteers in the US. Figure 6 shows that there were elevated anti-gp63 antibody levels among VL patients (mean absorbance = 0.89). In fact, 84% (42/50) of the VL patient sera tested have absorbance values greater than 3 standard deviations above the mean of normal control sera. The remaining 16% had relatively low levels of gp63-specific antibody, despite generally high titers of leishmania-specific antibody (mean absorbance value of 1.54). In contrast, cutaneous and mucosal leishmaniasis patients showed very little sero-reactivity with only two mucosal patients having absorbance values significantly above control normals. No sera samples from patients with a T cruzi infection or leprosy showed significantly elevated antibody levels to rgp63. These results indicate that gp63 is a potent B cell immunogen among VL patients although alone is not as good of an antigen in a diagnostic assay as is K39. However, the combination antigens of K39 and gp63 can provide a superior diagnostic kit with a reduced number of false positive results. EXAMPLE 1 This example illustrates the cloning of the K39 antigen. A genomic library was constructed with mechanically sheared DNA of L. chagasi (MHOM/BR/82/BA-2,Cl) in the expression vector lambda ZAPII according to the manufacturer's protocols (Stratagene, La Jolla, CA). Recombinants were screened with serum (obtained from a patient recently treated for acute L. donovani infection) preadsorbed to remove anti-E. coli reactivity according to the procedure described in Sambrook et al. Molecular Cloning, A Laboratory Manual, 2nd Ed. (Cold Spring Harbor, NY, 1989). The K39 clone was expressed to produce rK39 polypeptide and this was purified from a 25% to 40% ammonium sulfate fraction of a soluble bacterial lysate by preparative isoelectric focusing with a Bio-Rad Rotofor IEF cell and 1% 3/10 ampholytes (Bio-Rad, Richmond, CA) in the presence of 8 M urea and 10 mM dithiothreitol. Peak fractions were concentrated by a second ammonium sulfate precipitation, and dialyzed against 25 M Tris-HCl (pH 8), 150 M NaCl (TBS). Protein concentrations were determined using a Pierce BCA protein assay (Pierce, Rockford, IL) and purity assessed by Coomassie-blue staining following SDS-PAGE. A radiolabeled insert of K39 was used to screen the L. chagasi genomic library to obtain clones containing sequences flanking the K39 gene fragment. A set of overlapping deletions of clones K39 and LcKin were generated by controlled Exonuclease III digestion (according to the procedure described in Henikoff, Gene 28:351, 1984) to obtain a complete sequence of both the coding and noncoding strands. Single stranded template was prepared as described in Burns et al. (Proc. Natl. Acad. Sci. USA 89:1239, 1992) and nucleotide sequence was obtained by the Sanger dideoxynucleotide chain termination method using 35 S-labeled dATP (Sanger et al, Proc. Natl. Acad. Sci. USA 74:5463, 1977) or by fluorescence-based sequencing on an Applied Biosystems Sequencer Model 373A, according to the manufacturer's protocols. Sequence comparisons were made with GenPept (72.0) and Swiss-Prot (22.0) with the Lipman/Pearson method (Pearson and Lipman, Proc, Natl. Acad. Sci. USA 85:2444, 1988). Secondary structural predictions were made according to Garner et al. (J. Mol. Biol. 120:97, 1978) and Chou et al. (Advances in Enzymology 47:45, 1978). DNA from Leishmania spp. and T. cruzi (MHOM/CH/00/Tulahuen C2) were isolated, digested with Pst I, separated by agarose gel electrophoresis, and analyzed by Southern blotting. The blots were probed with a 2.4 kb Hind III fragment of LcKin derived from the 5' end of the gene (probe A) or a 915 bp insert of clone K39 (probe B). Each probe was radiolabeled with α- 32 P (dCTP) to a specific activity of 9 x 10 8 cpm/μg using random oligonucleotides as primers (Boehinger Manheim, Indianapolis). The final washes were for 1 hr in 0.1X SSC/0.5% SDS at 68 °C. Blots of L. chagasi DNA digested with Bam HI, Hind III and Pst I and no Hind III restriction sites were used and probed as above to assess gene copy. Probe A contained one Bam HI, one Pst I, and no Hind III restriction sites. Probe B did not contain sites for these restriction enzymes. Figure 3 A shows the blot of probe A and Figure 3B shows the blot of probe B. Probe A hybridized strongly to multiple Pst I restriction fragments of all Leishmania spp. tested (Figure 3A, lanes 3-9), indicating conservation in the kinesin homology domain. Polymorphism in size and number of hybridizing restriction sites were noted. Less conservation in the repetitive domain of the LcKin gene was observed as probe B hybridized with varying intensity to Pst 1 restriction fragments of L. chagasi (MHOM/BR/82/BA-2,Cl), L. amazonensis (IFLA/BR/67/PH8), L. braziliensis (MHOM/BR/75/M2903, obtained from Dr. Diane McMahon-Pratt, Yale University, New Haven, CT), L. donovani (MHOM/Et/67/HU3), L. infantum (IPT-1, obtained from Dr. Lee Schnur, Hebrew University-Hadassah Medical School, Jerusalem, Israel), and L. major (LTM p-2, obtained from Dr. David Moser, Temple Univ. Phila, PA), but not L. guyanesis (MHOM/BR/75/M4147) (Figure 3B, lanes 3-9). Given the intensity of the hybridization signals, the K39 repeat sequence appeared to be most closely related between L. chagasi and L. donovani (Figure 3B, lanes 3 and 7). No hybridization with either probe was observed with T. cruzi DNA (Figure 3, lane 10). Using L. chagasi digested DNA, two Pst I fragments were detected with probe B, indicating the presence of a second copy of the LcKin gene or polymorphism in restriction sites present in the 3' repetitive sequences (Figure 3B, lane 3). Probe A hybridized to three fragments in each of the Bam HI, Hind III, and Pst I digests of L. chagasi DNA (Figure 3A, lanes 1-3). Taken together, the Southern blot data show that the LcKin gene is present in a minimum of 2-3 copies in the L. chagasi genome, and that related sequences are present in the seven species of Leishmania examined. EXAMPLE 2 This example illustrates the identification of native LcKin antigen. Rabbit anti- rK39 serum was used to probe SDS-PAGE blots of L. chagasi promastigote and tissue amastigote lysates to partially characterize native LcKin protein. Promastigotes were cultured in axenic media. Tissue amastigotes were obtained from spleens of Syrian hamsters or footpads of Balb/c ByJ mice and purified as described in Burns et al. (J. Immunol. 146:742, 1991 ). Rabbit anti-rK39 serum was obtained by subcutaneous immunization of an adult New Zealand white rabbit (R & R Rabbitry, Stanwood, WA) with 200 μg of purified rK39 administered in Freund's incomplete adjuvant (IFA Gibco, Grand Island, NY) together with 100 mg of N-acetylmuramyl-L-alanyl-D- isoglutamine (muramyl dipeptide, Calbiochem, San Diego, CA). Five weeks later, the rabbit was boosted with 200 μg rK39 in IFA alone. Four weeks later, the rabbit was boosted intravenously with 25 μg of purified rK39. The rabbit serum was collected 6 days later. The antiserum bound specifically to purified rK39 (Figure 4A, lane 2) and to an approximately 230 kDa antigen present in amastigotes (Figure 4B, lane 6) and to a lesser degree in promastigotes (Figure 4B, lane 5). No reactivity with this serum was detected in promastigote and amastigote lysates of L. amazonensis (Figure 4B, lanes 7- 8) indicative of the variability within this repeat. Comparable amounts of lysate were loaded in all lanes as shown by reactivity of a rabbit anitserum raised against a constitutively expressed L. chagasi ribosomal phosphoprotein, Lc PO (Skeiky et al., ./. Exp. Med. 176:201 , 1992) (Figure 4C, inset). No reactivity was apparent in pre- immune serum (Figure 4A, lane 1, Figure 4B lanes 1-4). EXAMPLE 3 This example illustrates the reactivity of patient sera to recognize the rK39 antigen. Patient sera were obtained from well characterized Brazilian visceral, cutaneous and mucosal patients as well as T. cruzi infection sera from a study area in Bahia, Brazil. African visceral and cutaneous leishmaniasis sera were from biopsy- positive patients in the Sudan. Normal sera were from clinically healthy individuals living in endemic areas of the Sudan or from the U.S. The sera were analyzed by an immunoblot assay. Immunoblots of parasite lysates or purified rK39 were prepared as described in Burns et al. (J. Immunol. 146:742, 1991). Filters were blocked with TBS containing 5% non-fat dried milk and probed with patient sera (1 :250) or rabbit sera (1:400) diluted with TBS with 0.1% Tween-20 and 1% bovine serum albumin. Bound antibody was detected with 125 I-labeled Protein A (1 x 10 6 cpm/blot) followed by autoradiography. Both rK39 and L. chagasi promastigote lysates were strongly recognized by L. chagasi (Figure 2 A-C) and L. donovani (Figure 2 D-F) infection sera. Reactivity with rK39 was not observed with pools of sera obtained from mucosal (Figure 2G) or cutaneous (Figure 2H) leishmaniasis patient sera or with a pool of Chagas' disease (e.g., T. cruzi) patient sera (Figure 21). The pools of sera obtained from mucosal or cutaneous leishmaniasis Chagas' disease patient sera reacted strongly with promastigote lysates. These data indicate that the K39 antigen is specific to L. chagasi and L. donovani and/or K39 induces a strong antibody response only in VL patients. EXAMPLE 4 This example illustrates reactivity of patient sera with rK39 as determined by an ELISA. The patient sera were obtained as described in Example 3. The ELISA was conducted by diluting rK39 or L. chagasi promastigote lysate in coating buffer (15 M Na 2 HCO 3 , 28 mM NaH 2 CO 3 . pH 9.6) to 1 μg/ml or 20 μg/ml, respectively. Microassay plates (Probind, Falcon, Lincoln Park, NJ) were sensitized with rK39 (50 ng) or promastigote lysate (lμg/ml) by overnight incubation at 4 °C. Plates were blocked with PBS plus 1% Tween-20 for 1 hr at room temperature. After five washes with PBS containing 0.1% Tween-20 (PBS-T), 50 μl per well of sera diluted 1 :100 with PBS-T were incubated for 30 min at room temperature. The wells were again washed five times with PBS-T and bound antibody was detected by Protein A-HRP (Zymed, So San Francisco, CA) as described in Reed et al. (Am. J. Trop. Med. Hyg. 43:632, 1990). Absorbance values are relative to the mean of five control sera assayed on each plate. ELISA values of at least three standard deviations greater than the mean absorbance of the normal control sera were considered positive. I observed a high level of reactivity among VL patients with 98.2% (56 of 57) of Brazilian VL sera and 100% (52 of 52) of Sudanese VL sera exhibiting positive absorbance values. The positive absorbance values ranged from 0.05 to >2.0 (mean = 1.38) among Brazilian VL sera (Figure 5A) and from 0.094 to >2.0 (mean = 1.60) among Sudanese sera (Figure 5B). Detectable antibody to rK39 was restricted to VL patients, as little or no anti-rK39 response was observed in sera from mucosal or cutaneous leishmaniasis patients or T. cruzi infection sera, despite some reactivity in these latter samples with crude L. chagasi lysate (Figure 5). EXAMPLE 5 This example illustrates a method for producing and purifying recombinant gp63 (rgp63). Recombinant gp63 from L. chagasi and L. donovani was produced in E. coli as a non-fusion protein using T7 RNA polymerase expression system and pET plasmid expression vectors as described in Button et al. (Mol. Biochem. Parasitol. 44:213, 1991). Induced bacterial pellets were resuspended in lysis buffer (LB, 50 mM Tris HCl, pH 8.0, 100 mM NaCl, 10 mM EDTA) and lysed by treatment with lysozyme and sonication. The inclusion body fraction containing rgp63 was recovered by centrifugation for 5 min at 200 x g and washed twice in LB with 4 M urea as a chaotropic agent. The final pellet containing rgp63 was solubilized in 100 mM Tris, pH 8.5, containing 8 M urea and 100 mM dithiotretiol. Following dialysis, rgp63 was isolated by ammonium sulfate fractionation, followed by preparative isoelectric focusing in the presence of 8 M urea with 3/10 ampholytes using a Rotofor IEF cell (Bio-Rad, Richmond, CA) as described in Reed et al. (Am. J. Trop. Med. Hyg. 44:272, 1991). Protein concentrations of rgp63 were determined using the Pierce BCA protein assay (Pierce, Rockford, IL) and purity assessed by silver-staining (Bio-Rad) after SDS-PAGE as described in Laemmli (Nature 227:680, 1970). SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: Reed, Steven (ii) TITLE OF INVENTION: Diagnosis of Leishmaniasis (iii) NUMBER OF SEQUENCES: 3 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Immunex Corporation (B) STREET: 51 University Street (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: USA (F) ZIP: 98101 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: Apple Macintosh (C) OPERATING SYSTEM: Apple System 7.1 (D) SOFTWARE: Microsoft Word, version 5.1a (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US/08/006, 676 (B) FILING DATE: 15-JAN-1993 (viii) ATTORNEY INFORMATION: (A) NAME: Perkins, Patricia Anne (B) REGISTRATION NUMBER: 34,693 (C) REFERENCE/DOCKET NUMBER: 5004-WO (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (206) 587-0430 (B) TELEFAX: (206) 233-0644 (2) INFORMATION FOR SEQ ID NO. : 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 955 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Met His Pro Ser Thr Val Arg Arg Glu Ala Glu Arg Val Lys Val 1 5 10 15 Ser Val Arg Val Arg Pro Leu Asn Glu Arg Glu Asn Asn Ala Pro 20 25 30 Glu Gly Thr Lys Val Thr Val Ala Ala Lys Gin Ala Ala Ala Val 35 40 45 Val Thr Val Lys Val Leu Gly Gly Ser Asn Asn Ser Gly Ala Ala 50 55 60 Glu Ser Met Gly Thr Ala Arg Arg Val Ala Gin Asp Phe Gin Phe 65 70 75 Asp His Val Phe Trp Ser Val Glu Thr Pro Asp Ala Cys Gly Ala 80 85 90 Thr Pro Ala Thr Gin Ala Asp Val Phe Arg Thr lie Gly Tyr Pro 95 100 105 Leu Val Gin His Ala Phe Asp Gly Phe Asn Ser Cys Leu Phe Ala 110 115 120 Tyr Gly Gin Thr Gly Ser Gly Lys Thr Tyr Thr Met Met Gly Ala 120 125 130 135 Asp Val Ser Ala Leu Ser Gly Glu Gly Asn Gly Val Thr Pro Arg 140 145 150 lie Cys Leu Glu lie Phe Ala Arg Lys Ala Ser Val Glu Ala Gin 155 160 165 Gly His Ser Arg Trp lie Val Glu Leu Gly Tyr Val Glu Val Tyr 170 175 180 Asn Glu Arg Val Ser Asp Leu Leu Gly Lys Arg Lys Lys Gly Val 185 190 195 Lys Gly Gly Gly Glu Glu Val Tyr Val Asp Val Arg Glu His Pro 200 205 210 Ser Arg Gly Val Phe Leu Glu Gly Gin Arg Leu Val Glu Val Gly 215 220 225 Ser Leu Asp Asp Val Val Arg Leu lie Glu lie Gly Asn Gly Val 230 235 240 Arg His Thr Ala Ser Thr Lys Met Asn Asp Arg Ser Ser Arg Ser 245 250 255 His Ala lie lie Met Leu Leu Leu Arg Glu Glu Arg Thr Met Thr 260 265 270 Thr Lys Ser Gly Glu Thr lie Arg Thr Ala Gly Lys Ser Ser Arg 275 280 285 Met Asn Leu Val Asp Leu Ala Gly Ser Glu Arg Val Ala Gin Ser 290 295 300 Gin Val Glu Gly Gin Gin Phe Lys Glu Ala Thr His lie Asn Leu 305 310 315 Ser Leu Thr Thr Leu Gly Arg Val lie Asp Val Leu Ala Asp Met 320 325 330 Ala Thr Lys Gly Ala Lys Ala Gin Tyr Ser Val Ala Pro Phe Arg 335 340 345 Asp Ser Lys Leu Thr Phe lie Leu Lys Asp Ser Leu Gly Gly Asn 350 355 360 Ser Lys Thr Phe Met lie Ala Thr Val Ser Pro Ser Ala Leu Asn 365 370 375 Tyr Glu Glu Thr Leu Ser Thr Leu Arg Tyr Ala Ser Arg Ala Arg 380 385 390 Asp lie Val Asn Val Ala Gin Val Asn Glu Asp Pro Arg Ala Arg 395 400 405 Arg lie Arg Glu Leu Glu Glu Gin Met Glu Asp Met Arg Gin Ala 410 415 420 Met Ala Gly Gly Asp Pro Ala Tyr Val Ser Glu Leu Lys Lys Lys 425 430 435 Leu Ala Leu Leu Glu Ser Glu Ala Gin Lys Arg Ala Ala Asp Leu 440 445 450 Gin Ala Leu Glu Arg Glu Arg Glu His Asn Gin Val Gin Glu Arg 455 460 465 Leu Leu Arg Ala Thr Glu Ala Glu Lys Ser Glu Leu Glu Ser Arg 470 475 480 Ala Ala Ala Leu Gin Glu Glu Met Thr Ala Thr Arg Arg Gin Ala 485 490 495 Asp Lys Met Gin Ala Leu Asn Leu Arg Leu Lys Glu Glu Gin Ala 500 505 510 Arg Lys Glu Arg Glu Leu Leu Lys Glu Met Ala Lys Lys Asp Ala 515 520 525 Ala Leu Ser Lys Val Arg Arg Arg Lys Asp Ala Glu lie Ala Ser 530 535 540 Glu Arg Glu Lys Leu Glu Ser Thr Val Ala Gin Leu Glu Arg Glu 545 550 555 Gin Arg Glu Arg Glu Val Ala Leu Asp Ala Leu Gin Thr His Gin 560 565 570 Arg Lys Leu Gin Glu Ala Leu Glu Ser Ser Glu Arg Thr Ala Ala 575 580 585 Glu Arg Asp Gin Leu Leu Gin Gin Leu Thr Glu Leu Gin Ser Glu 590 595 600 Arg Thr Gin Leu Ser Gin Val Val Thr Asp Arg Glu Arg Leu Thr 605 610 615 Arg Asp Leu Gin Arg lie Gin Tyr Glu Tyr Gly Glu Thr Glu Leu 620 625 630 Ala Arg Asp Val Ala Leu Cys Ala Ala Gin Glu Met Glu Ala Arg 635 640 645 Tyr His Ala Ala Val Phe His Leu Gin Thr Leu Leu Glu Leu Ala 650 655 660 Thr Glu Trp Glu Asp Ala Leu Arg Glu Arg Ala Leu Ala Glu Arg 665 670 675 Asp Glu Ala Ala Ala Ala Glu Leu Asp Ala Ala Ala Ser Thr Ser 680 685 690 Gin Asn Ala Arg Glu Ser Ala Cys Glu Arg Leu Thr Ser Leu Glu 695 700 705 Gin Gin Leu Arg Glu Ser Glu Glu Arg Ala Ala Glu Leu Ala Ser 710 715 720 Gin Leu Glu Ala Thr Ala Ala Ala Lys Ser Ser Ala Glu Gin Asp 725 730 735 Arg Glu Asn Thr Arg Ala Thr Leu Glu Gin Gin Leu Arg Glu Ser 740 745 750 Glu Ala Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu Ala Thr Ala 755 760 765 Ala Ala Lys Met Ser Ala Glu Gin Asp Arg Glu Asn Thr Arg Ala 770 775 780 Thr Leu Glu Gin Gin Leu Arg Asp Ser Glu Glu Arg Ala Ala Glu 785 790 795 Leu Ala Ser Gin Leu Glu Ser Thr Thr Ala Ala Lys Met Ser Ala 800 805 810 Glu Gin Asp Arg Glu Ser Thr Arg Ala Thr Leu Glu Gin Gin Leu 815 820 825 Arg Asp Ser Glu Glu Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu 830 835 840 Ser Thr Thr Ala Ala Lys Met Ser Ala Glu Gin Asp Arg Glu Ser 845 850 855 Thr Arg Ala Thr Leu Glu Gin Gin Leu Arg Glu Ser Glu Glu Arg 860 865 870 Ala Ala Glu Leu Ala Ser Gin Leu Glu Ser Thr Thr Ala Ala Lys 875 880 885 Met Ser Ala Glu Gin Asp Arg Glu Ser Thr Arg Ala Thr Leu Glu 890 895 900 Gin Gin Leu Arg Asp Ser Glu Glu Arg Ala Ala Glu Leu Ala Ser 905 910 915 Gin Leu Glu Ala Thr Ala Ala Ala Lys Ser Ser Ala Glu Gin Asp 920 925 930 Arg Glu Asn Thr Arg Ala Ala Leu Glu Gin Gin Leu Arg Asp Ser 935 940 945 Glu Glu Arg Ala Ala Glu Leu Ala Ser Gin 950 955 (3) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3319 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) ORIGINAL SOURCE: (A) ORGANISM: Leishmania chagasi (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 2: GCTCCCACGG CGCTACCCCC TTTCCCGCAT GTGCGACAGT TTCACGCGTAC 51 AAACGTCTTT CTCTCTCCTT CGCGCGTGTC GCTATGGGCG GCGGCGCGTC 101 GGTGTCTTTG ATTGCACAGC TCACCGCCTC GCCATATTTT CGTCGTGGCC 151 ACGCGACCCC CCGACCTTCC CCTCCTCCGC CCCCAAAGAC AAGCCAGACA 201 TACCGACCAT GCCGTCTGCC CGCGTCTCTG CTTACCAAGC GCGCCACGCA 251 CCCCTTCCTC GGCCCTGAAT CTTTCGCGCG GCGCCATACA TTGCATGCAC 301 GTCACTACGC CTGTACACCT TACACCTCCT CTTGCCCACC CCTTTCCCCT 351 TCTACACGCC TAACTACACA CACATATATA TATATATATA TAAAGCGCTC 401 AACGCACACA TACTGTGGCC AGTATTACTG CACCAACGTC TGCCTCTTCC 451 AGGATGCACC CTTCCACTGT GCGGCGTGAG GCGGAGCGGG TGAAGGTGTC 501 GGTGCGCGTG CGCCCCCTAA ACGAACGTGA AAACAATGCC CCGGAAGGGA 551 CGAAAGTGAC CGTTGCGGCG AAACAGGCGG CCGCCGTGGT GACGGTCAAG 601 GTCCTGGGAG GCAGCAACAA CAGCGGCGCC GCCGAGTCGA TGGGGACTGC 651 AAGGCGGGTA GCGCAGGACT TTCAGTTCGA CCACGTGTTC TGGTCTGTGG 701 AGACGCCGGA CGCGTGCGGC GCGACCCCCG CGACGCAGGC AGACGTGTTC 751 CGGACGATCG GGTACCCGCT GGTGCAGCAC GCGTTCGACG GGTTCAACTC 801 GTGCTTGTTT GCGTACGGGC AGACAGGGAG CGGGAAGACG TACACGATGA 851 TGGGCGCGGA CGTGAGCGCG CTTAGTGGTG AGGGCAACGG CGTGACGCCG 901 CGGATCTGCC TGGAGATCTT TGCGCGGAAG GCGAGCGTGG AGGCGCAGGG 951 GCACTCGCGG TGGATCGTGG AGCTGGGGTA CGTGGAGGTG TACAACGAGC 1001 GCGTGTCGGA CCTGCTTGGG AAGCGGAAGA AGGGTGTGAA GGGCGGCGGC 1051 GAGGAGGTGT ACGTGGACGT GCGCGAGCAC CCGAGCCGCG GCGTGTTCCT 1101 GGAGGGGCAG CGGCTGGTGG AGGTTGGGAG CCTGGACGAT GTTGTGCGGC 1151 TGATCGAGAT CGGCAACGGC GTGCGGCACA CCGCTTCGAC GAAGATGAAC 1201 GACCGGAGCA GCCGGAGCCA CGCGATCATC ATGCTGCTGC TGCGCGAGGA 1251 GCGGACGATG ACGACGAAGA GCGGGGAGAC GATCCGTACT GCCGGCAAGA 1301 GCAGCCGCAT GAACCTTGTG GACCTTGCGG GGTCTGAGCG CGTGGCGCAG 1351 TCGCAGGTGG AGGGGCAGCA GTTCAAGGAG GCGACGCACA TCAACCTGTC 1401 GCTGACGACG CTCGGGCGCG TGATCGACGT GCTCGCGGAC ATGGCGACGA 1451 AGGGTGCGAA GGCGCAGTAC AGCGTTGCGC CGTTCCGCGA CTCGAAGCTG 1501 ACGTTCATCC TGAAGGACTC GCTTGGCGGG AACTCGAAGA CGTTCATGAT 1551 CGCGACTGTG AGCCCGAGCG CGCTGAACTA CGAGGAGACG CTGAGCACGC 1601 TGCGGTACGC GTCGCGCGCG CGCGACATTG TGAATGTTGC GCAGGTGAAC 1651 GAGGACCCGC GCGCACGGCG GATCCGCGAG CTGGAGGAGC AGATGGAGGA 1701 CATGCGGCAG GCGATGGCTG GCGGCGACCC CGCGTACGTG TCTGAGCTGA 1751 AGAAGAAGCT TGCGCTGCTG GAGTCGGAGG CGCAGAAGCG TGCGGCGGAC 1801 CTGCAGGCGC TGGAGAGGGA GCGGGAGCAC AACCAGGTGC AGGAGCGGCT 1851 GCTGCGCGCG ACGGAGGCGG AGAAGAGCGA GCTGGAGTCG CGTGCGGCTG 1901 CGCTGCAGGA GGAGATGACC GCGACTCGAC GGCAGGCGGA CAAGATGCAG 1951 GCGCTGAACC TGCGGCTGAA GGAAGAGCAG GCGCGCAAGG AGCGCGAGCT 2001 GCTGAAAGAG ATGGCGAAGA AGGACGCCGC GCTCTCGAAG GTTCGGCGAC 2051 GCAAAGACGC CGAGATAGCA AGCGAGCGCG AGAAGCTGGA GTCGACCGTG 2101 GCGCAGCTGG AGCGTGAGCA GCGCGAGCGC GAGGTGGCTC TGGACGCATT 2151 GCAGACGCAC CAGAGAAAGC TGCAGGAAGC GCTCGAGAGC TCTGAGCGGA 2201 CAGCCGCGGA AAGGGACCAG CTGCTGCAGC AGCTAACAGA GCTTCAGTCT 2251 GAGCGTACGC AGCTATCACA GGTTGTGACC GACCGCGAGC GGCTTACACG 2301 CGACTTGCAG CGTATTCAGT ACGAGTACGG GGAAACCGAG CTCGCGCGAG 2351 ACGTGGCGCT GTGCGCCGCG CAGGAGATGG AGGCGCGCTA CCACGCTGCT 2401 GTGTTTCACC TGCAAACGCT CCTGGAGCTC GCAACCGAGT GGGAGGACGC 2451 ACTCCGCGAG CGTGCGCTTG CAGAGCGTGA CGAAGCCGCT GCAGCCGAAC 2501 TTGATGCCGC AGCCTCTACT TCCCAAAACG CACGTGAAAG CGCCTGCGAG 2551 CGGCTAACCA GCCTTGAGCA GCAGCTTCGC GAATCCGAGG AGCGCGCTGC 2601 GGAGCTGGCG AGCCAGCTGG AGGCCACTGC TGCTGCGAAG TCGTCGGCGG 2651 AGCAGGACCG CGAGAACACG AGGGCCACGC TAGAGCAGCA GCTTCGCGAA 2701 TCCGAGGCGC GCGCTGCGGA GCTGGCGAGC CAGCTGGAGG CCACTGCTGC 2751 TGCGAAGATG TCAGCGGAGC AGGACCGCGA GAACACGAGG GCCACGCTAG 2801 AGCAGCAGCT TCGTGACTCC GAGGAGCGCG CTGCGGAGCT GGCGAGCCAG 2851 CTGGAGTCCA CTACTGCTGC GAAGATGTCA GCGGAGCAGG ACCGCGAGAG 2901 CACGAGGGCC ACGCTAGAGC AGCAGCTTCG TGACTCCGAG GAGCGCGCTG 2951 CGGAGCTGGC GAGCCAGCTG GAGTCCACTA CTGCTGCGAA GATGTCAGCG 3001 GAGCAGGACC GCGAGAGCAC GAGGGCCACG CTAGAGCAGC AGCTTCGCGA 3051 ATCCGAGGAG CGCGCTGCGG AGCTGGCGAG CCAGCTGGAG TCCACTACTG 3101 CTGCGAAGAT GTCAGCGGAG CAGGACCGCG AGAGCACGAG GGCCACGCTA 3151 GAGCAGCAGC TTCGTGACTC CGAGGAGCGC GCTGCGGAGC TGGCGAGCCA 3201 GCTGGAGGCC ACTGCTGCTG CGAAGTCGTC GGCGGAGCAG GACCGCGAGA 3251 ACACGAGGGC CGCGTTGGAG CAGCAGCTTC GTGACTCCGA GGAGCGCGCC 3301 GCGGAGCTGG CGAGCCAG 3319 (4) INFORMATION FOR SEQ ID NO. 3 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Xaa at position 7 is Asp or Glu, at position 10 is Glu or Ala, at position 21 is Ala or Ser, at position 23 is Ala or Thr, at position 27 is Met or Ser, at position 35 is Asn or Ser, and at position 39 is Thr or Ala (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Leu Glu Gin Gin Leu Arg Xaa Ser Glu Xaa Arg Ala Ala Glu Leu 1 5 10 15 Ala Ser Gin Leu Glu Xaa Thr Xaa Ala Ala Lys Xaa Ser Ala Glu 20 25 30 Gin Asp Arg Glu Xaa Thr Arg Ala Xaa 35

Claims: 'aims I claim: 1. A method for diagnosing leishmaniasis comprising: (a) obtaining a sample from a patient suspected of being infected with a Leishmania parasite, wherein the sample contains antibodies from the patient; and (b) determining the presence of antibodies that bind to a K39 repeat unit antigen from the sample. 2. The method of claim 1 wherein the sample is a serum sample or a plasma sample. 3. The method of claim 1 wherein the K39 repeat unit antigen is one or a plurality of K39 repeat sequences, wherein the K39 repeat sequence comprises the amino acid sequence Leu Glu Gin Gin Leu Arg Xaa Ser Glu Xaa Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu Xaa Thr Xaa Ala Ala Lys Xaa Ser Ala Glu Gin Asp Arg Glu Xaa Thr Arg Ala Xaa (SEQ ID NO:3), wherein Xaa at position 7 is Asp or Glu, at position 10 is Glu or Ala, at position 21 is Ala or Ser, at position 23 is Ala or Thr, at position 27 is Met or Ser, at position 35 is Asn or Ser, and at position 39 is Thr or Ala. 4. The method of claim 1, further comprises the step of determining the presence of antibodies that bind to a native or recombinant gp63 polypeptide. 5. A diagnostic kit for evaluating a patient antibody-containing sample for the presence of zw -Leishmania parasite antibodies, comprising a K39 repeat unit antigen. 6. The diagnostic kit of claim 5, wherein the K39 repeat unit antigen is bound to a solid phase. 7. The diagnostic kit of claim 5, wherein the kit further comprises an anti- human antibody conjugated to a detection moiety. 8. The diagnostic kit of claim 5, wherein the K39 repeat unit antigen is one or a plurality of K39 repeat sequences, wherein the K39 repeat sequence comprises the amino acid sequence Leu Glu Gin Gin Leu Arg Xaa Ser Glu Xaa Arg Ala Ala Glu Leu Ala Ser Gin Leu Glu Xaa Thr Xaa Ala Ala Lys Xaa Ser Ala Glu Gin Asp Arg Glu Xaa Thr Arg Ala Xaa (SEQ ID NO:3), wherein Xaa at position 7 is Asp or Glu, at position 10 is Glu or Ala, at position 21 is Ala or Ser, at position 23 is Ala or Thr, at position 27 is Met or Ser, at position 35 is Asn or Ser, and at position 39 is Thr or Ala. 9. The diagnostic kit of claim 5, further comprising a gp63 polypeptide, in combination with the K39 repeat unit antigen.

Inventors: REED STEVEN G, REED, STEVEN, G.
Applicants: IASYS CORP, IASYS CORPORATION
Application year: 1994
Main classification: G01N33
IPC codes: C07K14, G01N33